Pozen.

• Position: Triangle - Royalties - Brief Article

CHAPEL HILL -- Pozen sold U.S. commercialization rights for MT 300, its injectible migraine treatment, to San Diego-based Xcel Pharmaceuticals. Xcel will pay $2 million upfront and up to $8 million more if MT 300 wins regulatory approval from the federal Food and Drug Administration, expected by early 2004, and...